Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy ...

Board director Andrew Stevens says the gap at the top end of town will never close unless executive roles can be redesigned to better suit women.

High-pay, low-effort jobs give a wide array of freelancers the chance to earn $40 or more per hour, largely working when they ...

Abstract: Log analysis is challenging due to the unstructured nature of $\log$ messages. Most prior methods are limited to specific $\log$ formats and require substantial labeled data. Recent natural ...

Gov. Andy Beshear announced the first large scale private sector investment in Carlisle County in more than a decade on Feb.

A sprawling Chinese influence operation — accidentally revealed by a Chinese law enforcement official’s use of ChatGPT — focused on intimidating Chinese dissidents abroad, including by impersonating ...

CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the ...

Consulting firm keen to increase uptake of technology and is reportedly monitoring adoption by workforce Accenture has reportedly started tracking staff use of its AI tools and will take this into ...

Simply sign up to the Accounting & Consulting services myFT Digest -- delivered directly to your inbox. Accenture has begun monitoring staff use of its AI tools as part of how it decides top-level ...

Our editors' top picks to read today. Anyone can view a sampling of recent comments, but you must be a Times subscriber to contribute. Log in above or subscribe here. Conversations are opinions of our ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection. Australia-based CSL picked ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...